Jentadueto is an anti-diabetic drug owned by Boehringer Ingelheim. It contains active ingredients Linagliptin and Metformin Hydrochloride. The drug was first authorized for market use on 30th January 2012.
The generic version of Jentadueto may possibly be released after 4th December 2030. This is primarily determined by the expiration date of its last active patent. Previous patents, such as US8119648 and US8178541, have already expired.
Jentadueto is particularly effective in treating type 2 diabetes mellitus. This is achieved by administering a dipeptidyl peptidase-iv inhibitor (Linagliptin) in combination with metformin and/or a sulfonylurea. The pharmaceutical composition of this drug, which includes Linagliptin, Metformin, and a basic amino acid, contributes significantly to its effectiveness in treating type 2 diabetes.
Jentadueto holds a total of 18 patents, two of which have expired. The expiry date of its last patent is expected to be on 4th December 2030, facilitating the potential release of Jentadueto generics. Below are the details of the patent: